---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-044212"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2024-10-25T23:59:59+00:00"
generated_at: "2026-05-30T10:01:06.488743+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Acasti Pharma rebrands as Grace Therapeutics; new ticker GRCE effective Oct 28

## Summary
- Company renamed Grace Therapeutics, Inc.; common stock begins trading as GRCE on Nasdaq at market open Oct 28, 2024.
- GTx-104 (nimodipine for aSAH) STRIVE-ON trial fully enrolled; data readout expected early 2025, NDA submission H1 2025.
- Virtual KOL event on GTx-104 scheduled for Nov 20, 2024 at 2pm ET.
- Company completed restructuring, rebuilt management, divested legacy assets, re-domiciled to Delaware.
- Addressable U.S. market for GTx-104 estimated at ~$300M; GTx-102 and GTx-101 development deprioritized.

## SEC filing metadata
- accession: 0001140361-24-044212
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2024-10-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000114036124044212/0001140361-24-044212-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000114036124044212/ef20037632_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-044212
- JSON: https://secwatch.observer/filing/0001140361-24-044212.json
- Plain text: https://secwatch.observer/filing/0001140361-24-044212.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.